diuretics
in review
5 min read
Updated 2026-10-21
diuretics
Each class blocks Na⁺ reabsorption at one nephron segment; potency follows how much Na⁺ that segment handles and how much the downstream segments can reclaim. Loops are the most potent and the decongestion backbone; thiazides, acetazolamide and amiloride are add-ons, blood pressure drugs, or electrolyte tools. Choosing and escalating diuretics in acute HF → diuretic therapy in acute heart failure. MRAs → mineralocorticoid receptor antagonists; vaptans → tolvaptan; SGLT2i → SGLT2 inhibitors.
by segment
| class | site / transporter | FENa potency | urine | acid–base | K⁺ | Ca²⁺ |
|---|---|---|---|---|---|---|
| acetazolamide | proximal tubule — carbonic anhydrase | ~4% | NaHCO₃-rich | metabolic acidosis | ↓ | — |
| loop | thick ascending limb — NKCC2 | 20–25% | dilute (hypotonic) | contraction alkalosis | ↓ | ↓ (calciuric) |
| thiazide | distal convoluted tubule — NCC | 5–8% | concentrated | alkalosis | ↓↓ | ↑ (retains) |
| amiloride | collecting duct — ENaC | ~2% | — | mild acidosis | ↑ | — |
- loops, thiazides and acetazolamide are protein-bound and reach the lumen by proximal tubular secretion → low renal blood flow, hypoalbuminaemia and CKD blunt them; amiloride too
- loops and thiazides waste Cl⁻ → hypochloraemic alkalosis → renin ↑ → diuretic resistance; acetazolamide spares Cl⁻
- loops cause hypernatraemia (lose free water); thiazides cause hyponatraemia (block the diluting segment)
loop diuretics
| furosemide | bumetanide | torsemide | ethacrynic acid | |
|---|---|---|---|---|
| oral equivalent | 40 mg | 0.5–1 mg | 10–20 mg | — |
| oral bioavailability | 10–100% (erratic; gut oedema) | 80–100% | 80–100% | — |
| IV vs oral | double IV dose for oral (CCS: ~50% bioavailability) | IV ≈ oral | IV ≈ oral | — |
| half-life | 1.5–3 h | 1–1.5 h | 3–6 h | — |
| max IV daily dose | 400–600 mg (up to 1000 mg in severe CKD) | 10–15 mg | 200–300 mg | — |
| sulfonamide | yes | yes | yes | no |
- threshold drug: nothing below the natriuretic threshold (rises as GFR falls); above the ceiling, a bigger dose only prolongs the effect → dose for threshold, frequency for duration (usually 2–3×/day, ≥6 h apart, to avoid rebound Na⁺ retention; once daily if response is good)
- dosing in ADHF (naive ≥20–40 mg IV; chronic 1–2.5× home dose IV; DOSE-AHF) → diuretic therapy in acute heart failure
- erratic furosemide absorption → switch to bumetanide or torsemide; TRANSFORM-HF (2023): torsemide vs furosemide → same 12-month mortality
- no survival benefit from loops — symptom drugs
- other uses: hyperkalaemia (with intact renal function), hypercalcaemia after volume repletion, oedema of nephrotic syndrome and cirrhosis (with spironolactone)
- sulfonamide antibiotic allergy is not a contraindication (no N4-arylamine); ethacrynic acid only for documented allergy to the loop itself — more ototoxic
thiazide and thiazide-like diuretics
| agent | half-life | oral dose | role |
|---|---|---|---|
| chlortalidone | 45–60 h | 12.5–25 mg (HTN); up to 100 mg | hypertension; works in stage 4 CKD (CLICK (2021)); same CV outcomes as HCTZ with more hypokalaemia (6.0% vs 4.4%) |
| indapamide | 14–24 h | 1.25–2.5 mg | hypertension; less metabolic effect |
| hydrochlorothiazide | 6–15 h | 12.5–25 mg (HTN); 25–100 mg as diuretic add-on | common in combinations; weakest per mg |
| metolazone | 6–20 h | 2.5–10 mg (max 20) | add-on to loops in diuretic resistance; slow absorption — give hours before the loop |
| chlorothiazide | short | 500–1000 mg IV | IV add-on when NPO; give just before the loop |
- uses: hypertension — HTN Canada 2025 no longer prefers thiazide-like over thiazide; usually as a single-pill combination with ACEi/ARB; breaking distal-nephron resistance in HF (CLOROTIC (2023): more weight loss, more Cr rise and electrolyte disturbance, no outcome change); hypercalciuric stones; nephrogenic DI (paradoxical ↓ urine volume)
- effective at eGFR <30 — the “useless below 30” teaching is outdated for chlortalidone and metolazone
- chronic outpatient loop + thiazide → severe electrolyte disturbance that goes unnoticed → avoid without close lab follow-up
- AEs: hyponatraemia (stop if Na⁺ <125), hypokalaemia (2–3 K⁺ lost per Na⁺; worse with high aldosterone), hypercalcaemia, hyperuricaemia/gout, hyperglycaemia, hypomagnesaemia
acetazolamide
- inhibits proximal carbonic anhydrase → NaHCO₃ diuresis; spares Cl⁻ → more Cl⁻ reaches the macula densa → renin suppressed; corrects contraction alkalosis
- ADHF: 500 mg IV daily added to loop — ADVOR (2022): decongestion by day 3 42% vs 31%, stay 1 day shorter, no change in death or readmission; best with alkalosis or hypochloraemia → diuretic therapy in acute heart failure
- self-limiting: the acidosis it causes reduces filtered HCO₃⁻ → effect wanes over 2–3 days
- other uses: metabolic alkalosis (e.g. post-hypercapnic, diuretic-induced), acute mountain sickness, idiopathic intracranial hypertension, glaucoma
- max 500 mg TID; HF data are for IV — no outcome data for oral in ADHF
- avoid: hypercapnic or respiratory acidosis without ventilation (removes metabolic compensation), severe hepatic disease (encephalopathy), severe hypokalaemia
- AEs: metabolic acidosis, paraesthesias, hypokalaemia, AKI, sulfonamide-type rash; stones with chronic use
amiloride
- blocks ENaC directly (not via the aldosterone receptor) → onset ~2 h vs 48–72 h for spironolactone; weak natriuretic alone
- counteracts loop/thiazide side effects: ↓ K⁺ secretion, ↓ H⁺ secretion (alkalosis), ↓ Mg²⁺ wasting
- 5–10 mg PO daily (max 20); accumulates when GFR <50 (half-life up to 144 h) → start low, check K⁺
- specific uses: Liddle syndrome (ENaC gain of function); lithium-induced nephrogenic DI (blocks lithium entry via ENaC)
- avoid if K⁺ >5.0; hyperkalaemia additive with ACEi/ARB/MRA
- choose amiloride over triamterene (triamterene: stones, interstitial nephritis, AKI)
ototoxicity and electrolytes (all classes)
- ototoxicity (loops): tinnitus, reversible or permanent hearing loss → risk with rapid injection, severe renal impairment, above-recommended doses, hypoproteinaemia, aminoglycosides, ethacrynic acid → infuse high-dose IV furosemide ≤4 mg/min
- replace K⁺ as KCl (Cl⁻ is part of the fix); replace Mg²⁺ or K⁺ won’t correct
- K⁺-sparing partner (spironolactone 25 mg or amiloride) limits K⁺ and Mg²⁺ loss in combination regimens
Prepared 2026-10-21. Not yet verified — check every number against the sources.